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Abstract: Microbes are known to colonize surfaces and form biofilms. These biofilms are communities
of microbes encased in a self-produced matrix that often contains polysaccharides, DNA and proteins.
Antimicrobial peptides (AMPs) have been used to control the formation and to eradicate mature
biofilms. Naturally occurring or synthetic antimicrobial peptides have been shown to prevent
microbial colonization of surfaces, to kill bacteria in biofilms and to disrupt the biofilm structure.
This review systemically analyzed published data since 1970 to summarize the possible anti-biofilm
mechanisms of AMPs. One hundred and sixty-two published reports were initially selected for this
review following searches using the criteria ‘antimicrobial peptide’ OR ‘peptide’ AND ‘mechanism of
action’ AND ‘biofilm’ OR ‘antibiofilm’ in the databases PubMed; Scopus; Web of Science; MEDLINE;
and Cochrane Library. Studies that investigated anti-biofilm activities without describing the possible
mechanisms were removed from the analysis. A total of 17 original reports were included which have
articulated the mechanism of antimicrobial action of AMPs against biofilms. The major anti-biofilm
mechanisms of antimicrobial peptides are: (1) disruption or degradation of the membrane potential
of biofilm embedded cells; (2) interruption of bacterial cell signaling systems; (3) degradation of
the polysaccharide and biofilm matrix; (4) inhibition of the alarmone system to avoid the bacterial
stringent response; (5) downregulation of genes responsible for biofilm formation and transportation
of binding proteins.
Keywords: biofilm; antimicrobial peptides; mechanism of action; medical devices; biomaterials
1. Biofilms
A biofilm is a group of organisms such as fungi, bacteria, and viruses, existing in a sessile form and
surrounded by a self-produced extracellular matrix. Costerton et al. [1] proposed a basic definition of
biofilm as “a structured community of bacterial cells enclosed in a self-produced polymeric matrix and
adherent to an inert or living surface” and Hall-Stoodley et al. [2] defined biofilms as “surface-associated
microbial communities, surrounded by an extracellular polymeric substance (EPS) matrix”. A biofilm
can also be called “an aggregate of microbial cells adherent to a living or nonliving surface, embedded
within a matrix of EPS of microbial origin” [3]. Recently, biofilms have been described as complex
sessile communities of microbes found either attached to a surface or buried firmly in an extracellular
matrix as aggregates [4]. The matrix can be composed of exopolysaccharides, proteins, nucleic acids,
and other cellular debris collectively called extra polymeric substances (EPS) [5–7].
1.1. Biofilm Formation
The process of biofilm formation on biomaterials begins by the initial adhesion of planktonic
bacteria to surfaces and then aggregation into smaller groups of bacteria known as microcolonies.
Following attachment, EPS such as proteins, glycoproteins, glycolipids, and extracellular DNA are
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synthesized [8]. Glycopeptides, glycolipids and lipopolysaccharides help to keep the biofilms intact [9].
In mature biofilms, the microcolonies differentiate into distinct phenotypes which are significantly
different in gene expression than their planktonic counterparts [10]. The differentiation can be triggered
by the accumulation of quorum sensing molecules such as N-acyl homoserine lactones that facilitate
cell to cell communication [1].
Starvation conditions are known to promote the formation of biofilms, and bacteria grown or
living under starvation are known to have higher antibiotic tolerance. Biofilm formation can be an
adaptation of microorganisms to hostile environments [11,12]. Under hostile conditions bacteria can
activate the stringent response (which can be characterized by the production of “alarmones”) by
synthesizing the signaling nucleoside guanosine pentaphosphate or tetraphosphate ((p)ppGpp) which
can cause the inhibition of RNA synthesis when amino acids are in low concentrations [13]. RelA
and SpoT are homologous proteins that are responsible for modulating intracellular concentrations of
(p)ppGpp, often conserved among Gram-negative and Gram-positive bacteria, with a few exceptions
such as S. aureus [14]. This stringent response plays an important role in the development of biofilms
as mutants lacking RelA and SpoT produce comparatively fragile and antibiotic sensitive biofilms [15].
The exact role of (p)ppGpp in biofilm formation is not known, but it is likely that hostile conditions
trigger transcription of hundreds of genes responsible for altered intracellular metabolism and energy
conservation through suspension of cell division [15].
Biofilm formation can occur on a variety of surfaces, including living tissues, medical devices,
industrial or potable water system piping, or on surfaces in the natural aquatic environment [16].
Approximately 99% of the microbial world exists as biofilms [17,18] and these biofilms are diverse
containing a wide range of microbes [19]. For example, more than 500 types of bacteria are present in
biofilms in the oral cavity [20].
1.2. Characteristics of Biofilms
Biofilm embedded cells are not as sensitive to antimicrobials compared with their planktonic
counterparts. [21] They are highly resistant to conventional antibiotics, up to 1000 times more than
planktonic bacteria. This is related in part to the slow growth rate and low metabolic activity of cells
in biofilms [15,22,23]. In addition, the EPS matrix surrounding biofilms, which can make up to 50%
to 90% of the total biomass of biofilms, resists the penetration of antimicrobials [16,24–30]. Moreover,
microbes in biofilms can have a high rate of mutation and exchange of resistance genes on mobile
genetic elements [31,32] which can also lead to increase in the overall resistance of cells in biofilms.
1.3. Biofilm-Associated Infections
Biofilms pose a serious threat to public health because of their potential to cause biomaterial-
associated infections due in-part to the high resistance of biofilms to antimicrobials agents [33].
About 80% of bacterial infections in humans are caused by biofilms [1,12,23]. Biofilm mediated infection
can be divided into two categories, non-device and device associated infections [34,35].
The first category involves biofilm formation on host tissues such as epithelial, mucosal surfaces,
and teeth. These can cause infections associated with cystic fibrosis (CF) patients, foot ulcers in diabetic
patients, chronic otitis media or rhinosinusitis, chronic prostatitis, recurrent urinary tract infections,
and dental caries and periodontitis [36,37].
The second category of infections arises due to the microbial colonization of abiotic objects,
for example indwelling medical devices such as central venous or urinary catheters, joint or dental
prostheses, heart valves, endotracheal tubes, intrauterine devices, and dental implants [34,35,38].
Microbes can detach from these biofilms and disseminate to the surrounding tissues or to the
bloodstream, further exacerbating the infection [39]. Worldwide production of biomedical devices
and tissue engineering-related objects is approximately $180 billion per annum [37]. According to
current estimates, over 5 million medical devices or implants are used annually in the U.S.A. alone [37].
About 60–70% of nosocomial infections are associated with biomaterials or implants [37]. Regardless
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of the sophistication of the biomedical implant and tissue engineering constructs, all medical devices
are susceptible to microbial colonization and can cause infections [40–42]. Biofilm growth on medical
devices can be extremely difficult to eradicate, with only a few treatment options such as removal of
the infected device or use of large doses of antibiotics [43]. However, this increases treatment costs
and may increase the potential for the development of antibiotic resistance and cytotoxicity [44].
Moreover, removal may not be an easy option for patients with medical devices for critical care such
as pacemakers. The clinical significance of biofilm-associated infections and their inherent resistance
to antimicrobials urgently demand development of novel anti-biofilm compounds.
2. Antimicrobial Peptides
Antimicrobial peptides (AMPs) have a varying number (from five to over a hundred) of amino
acids, most commonly L forms, with molecular weights between 1–5 KDa. AMPs have a broad
spectrum of activity ranging from viruses to parasites [45]. AMPs are generally cationic in nature,
and often referred as cationic host defense peptides because of their role in the immune response [46].
They are also known as cationic amphipathic peptides [47], cationic AMPs [48], andα-helical AMPs [49].
Recently, a few anionic antimicrobial peptides have been reported which have a net charge ranging
from −1 to −7, and a length from 5 to circa 7 amino acid residues [50]. AMPs have been recognized as
promising alternatives to conventional antibiotics due to their multiple target sites and non-specific
mechanism of action which reduces the chances of resistance development. AMPs exhibit strong
anti-biofilm activity against multidrug resistant as well as clinically isolated bacterial biofilms [51].
AMPs can interfere in the early stages of biofilm formation to prevent the initial adhesion of bacteria to
surfaces [51]. They can destroy mature biofilms by encouraging microbial detachment or killing [52].
Here we focus on the anti-biofilm action of AMPs against different Gram-positive and Gram-negative
bacteria, with emphasis on their mechanism of action.
Based on their secondary structure, AMPs are generally categorized into four groups (1) α-helical
AMPs; (2) β-sheet AMPs; (3) extended AMPs; and (4) cationic loop AMPs [53]. Alpha-helical peptides
are the largest group of AMPs representing 30–50% of all AMPs of known secondary structure [54–56].
These peptides commonly consist of 12–40 amino acids and contain an abundance of helix stabilizing
amino acids such as alanine, leucine, and lysine [56]. Beta-sheet AMPs usually consist of two to ten
cysteine residues that from one to five inter-chain disulfide bonds that help the peptides to form
the beta-sheet [57]. Beta-sheet antimicrobial peptides include the defensin family of peptides [58,59].
Defensins consist of two to three antiparallel beta-sheets however, in some cases alpha-helical or
unstructured segments can be found at their N- or C-termini [60]. Compared withα-helical antimicrobial
peptides, the defensins adopt a globular structure in aqueous solutions [60,61]. Despite extensive
variations in length, amino acid composition and net positive charge, β-strands are observed in all α-
and β-defensins [62,63]. Extended AMPs are not folded into α-helix or β-sheet structures. These AMPs
often contain high numbers of arginine, tryptophan, proline or cystine residues [64]. Some of these AMPs
can fold into defined amphipathic molecules in bacterial membranes, but often these are not membrane
active [65]. The proline-rich insect-derived pyrrhocoricin, drosocin and apidaecin peptides penetrate
membranes and exert their antimicrobial activities by interacting with intracellular proteins such as
the heat-shock protein DnaK and GroEL to inhibit the DnaK ATPase and chaperone-assisted protein
folding related activities, respectively [66,67]. Cationic loop AMPs are proline-arginine rich peptides,
and because of their high numbers of proline residues, they rarely form amphipathic characteristics and
tend to adopt polyproline helical type-II structures [68].
2.1. Mechanism of Action of AMPs against Planktonic Bacteria
The mechanism of action of AMPs usually starts by interacting with negatively charged moieties
such as lipopolysaccharides (LPS) in the outer membranes of Gram-negative bacteria and lipoteichoic
acid (LTA) in the cell wall of Gram-positive bacteria [69–71]. Once AMPs cross or produce pores in the
outer membrane or the cell wall of bacteria, disruption of cytoplasmic membranes occurs followed by
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cell lysis [72]. The mechanisms of action of AMPs have been divided into pore-forming and non-pore
models [73]. Pore-forming models include the barrel stave and the toroidal pore models. Non-pore
models include the carpet model. AMPs can also inhibit the synthesis of cell walls, DNA, RNA and
protein, and activate enzymes such as autolysins that induce autolytic death [66,74,75].
2.2. Mechanism of Action against Biofilms
In this review, we systemically analyzed all published data since 1970 to summarize all the
possible anti-biofilm mechanisms of antimicrobial peptides. A total of 162 published reports were
initially selected for this review following search criteria using ‘antimicrobial peptide’ OR ‘peptide’
AND ‘mechanism of action’ AND ‘biofilm’ OR ‘antibiofilm’ in the databases PubMed, Scopus, Web of
Science, MEDLINE, and Cochrane Library. The studies investigated the antimicrobial activity of AMPs
against a variety of microorganisms. A total of 17 original reports qualified for our review which have
articulated the mechanism of anti-biofilm action of AMPs. These reports are included in this review.
Several overlapping anti-biofilm mechanisms of AMPs are reported in the literature. Following
careful consideration, we found five major anti-biofilm mechanisms: (1) disruption or degradation of
the membrane potential of biofilm embedded cells; (2) interruption of bacterial cell signaling systems;
(3) degradation of the polysaccharide and biofilm matrix; (4) inhibition of the alarmone system to
avoid the bacterial stringent response; (5) downregulation of genes responsible for biofilm formation
and transportation of binding proteins.
Certain synthetic AMPs can rapidly degrade pre-established biofilms of P. aeruginosa [52].
Although the mechanism of biofilm degradation is poorly understood, the rapid destruction of biofilm
embedded cells [52] may indicate that they act by disrupting the membranes of the bacteria. Table 1
and Figure 1 summarize the mechanisms of biofilm inhibition and degradation of various AMPs.
Mechanistic studies have tended to focus on the membrane-disrupting properties of AMPs [76,77].
(i) disruption or degradation of the membrane potential of biofilm embedded cells
Three bacteriocins (nisin A, lacticin Q, and nukacin ISK-1) can destroy the membrane potential
of biofilm embedded cells of S. aureus (an MRSA strain) and can cause the release of ATP from the
cells [78]. An engineered peptide RN3(5-17P22-36) [79] derived from the cationic proteins of eosinophil
granules [80,81] can kill bacteria via membrane disruption. However, this membrane depolarization of
cells in biofilms was 2–3-fold less compared with planktonic bacteria at the same concentration [79].
A frog skin-derived AMP esculentin (Esc (1-21) can permeabilize the cytoplasmic membrane of
P. aeruginosa PAO1 in biofilms and cause release of β-galactosidase [82]. However, this effect was
slower and did not result in comparable β-galactosidase release compared to its action on planktonic
cells [82]. The AMP (CSA)-13 can quickly penetrate into biofilms and permeabilize the cell membranes
of biofilm cells of P. aeruginosa [83].
(ii) interruption of the bacterial cell signaling system
Human cathelicidic LL-37 and indolicidin can prevent biofilm formation of P. aeruginosa possibly
by down-regulating the transcription of two major quorum-sensing systems, Las and Rhl [84].
Another mechanism by which AMPs have been shown to inhibit the formation of biofilms is by
increasing twitching motility in P. aeruginosa by stimulating the expression of genes needed for type IV
pilli biosynthesis and function [84,85]. The main function of type IV pilli is to increase the movement
of bacteria on surfaces, which may facilitate removal of cells [86].
(iii) degradation of the polysaccharide and biofilm matrix
AMPs can also act on the extracellular polymeric matrix of bacterial biofilms. For example,
peptide PI can degrade the EPS produced by Streptococcus mutans leading to reductions in biofilms
formed on polystyrene or and saliva-coated hydroxyapatite [87]. An anti-biofilm peptide derived from
maggots of the blowfly Calliphora vicina can degrade the biofilm matrix produced by drug resistant
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Escherichia coli, Staphylococcus aureus and Acinetobacter baumannii but the mechanism of degradation
was not investigated [88]. Human liver-derived antimicrobial peptide hepcidin 20 can reduce the mass
of extracellular matrix and alter the architecture of biofilms of S. epidermidis by targeting polysaccharide
intercellular adhesin (PIA) [89]. Another peptide S4(1–16) M4Ka, a derivative of S4, has been shown
to act against immature P. aeruginosa biofilms by disintegration and release of membrane lipids,
detachment of bacteria and inhibition of biofilm formation [90]. The fish derived AMP piscidin-3 has
nucleosidase activity and can destroy extracellular DNA of P. aeruginosa by coordinating with Cu2+
through its N-terminus [91].
(iv) inhibition of the alarmone system to avoid the bacterial stringent response
Anti-biofilm peptides may act by targeting an almost universal stringent stress response in both
Gram-positive and Gram-negative bacteria [92]. Many bacteria produce the signaling nucleotides
guanosine 5′-diphosphate 3′-diphosphate (ppGpp) and (p)ppGpp, that can regulate the expression
of a plethora of genes [93,94] and are important in biofilm formation [95]. The AMPs 1018, DJK-5,
and DJK-6 can block the synthesis and trigger degradation of (p)ppGpp in both Gram-positive and
Gram-negative bacteria, and this can lead to reduction in biofilm formation which in turn increases
susceptibility to AMPs [15]. Some other AMPs such as DJK-5 and 1018 can act on the stringent response
in P. aeruginosa by suppressing spoT promoter activity [96]. DJK-5 and DJK-6 can degrade (p)ppGpp
on P. aeruginosa biofilms to higher extent than 1018 [14].
(v) downregulation of genes responsible for biofilm formation and transportation of binding proteins
Biofilm formation by staphylococci is an accumulative process which crucially depends upon
the synthesis of polysaccharide intercellular adhesin molecule PIA encoded by icaADBC locus in
staphylococci [97]. Human β-defensin 3 (hBD-3) can reduce the expression of icaA, icaD and icaR genes
of Staphylococus epidermidis ATCC 35,984 thereby reducing biofilm formation [98]. AMPs can inhibit
genes controlling the mobility of extrachromosomal elements and transport and binding proteins [99].
A peptide Nal-P-113, can inhibit Porphyromonas gingivalis biofilm formation by down-regulating
genes such as PG0282 and PG1663 which encode ABC transporter and ATP-binding protein [99].
ABC transporters have been involved in cell-to-surface and cell-to-cell interactions in biofilms
formation [100,101]. Figure 2 summarizes the targets sites of representative anti-biofilm AMPs.
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Table 1. Representative AMPs and their anti-biofilm mechanism of action
AMPs Sources Amino Acids Sequence Microorganisms Proposed Mechanism of Action Ref
LL-37 Human LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES Pseudomonas aeruginosa Reduces swimming and swarming motilities,
promotes twitching motility, downregulates
the genes required for biofilm formation and
influences QS system
[84,85]
1037 Denovo KRFRIRVRV Pseudomonas aeruginosa
1018 Denovo VRLIVAVRIWRR Pseudomonas aeruginosa Decrease intracellular (p) PpGpp [14]
Esculentin-1a
(1–21) Denovo GIFSKLAGKKIKNLLISGLKG Pseudomonas aeruginosa Disrupts cell membrane [82]
Nisin A Denovo MSTKDFNLDLVSVSKKDSGASPR Staphylococcus aureus Depolarizes cell membrane [78]
lacticin Q Denovo MAGFLKVVQLLAKYGSKAVQMAWANKGKILDWLNAGQAIDKVVSKIKQILGIK Staphylococcus aureus Depolarizes cell membrane [78]
Nukacin ISK-1 Denovo KK-KSGVIPTVSHGCHMNSFQFVFTCC Staphylococcus aureus Depolarizes cell membrane [78]
RN3(5-17P22-36) Denovo RPFTRAQWFAIQHISPRTIAMRAINNYRWR Pseudomonas aeruginosa Depolarizes and permeabilize cellmembrane [79]
S4 (1–16) Denovo ALWKTLLKKVLKAAAK Pseudomonas aeruginosa Disintegrates and release membrane lipids [90]
P1 Calliphoravicina FVDRNRIPRSNNGPKIPIISNP
Escherichia coli,
Staphylococcus aureus,
Acinetobacter baumannii
Degrades biofilm matrix [88]
L-K6L9 Denovo LKLLKKLLKKLLKLL Pseudomonas aeruginosa Degrades biofilms matrix [52]
Piscidin-3 Fish FIHHIFRGIVHAGRSIGRFLTG Pseudomonas aeruginosa Degrades eDNA [91]
PI Tick PARKARAATAATAATAATAAT Streptococcus mutans Interferes and degrade EPS matrix [87]
Hepcidin 20 Human ICIFCCGCCHRSHCGMCCKT Staphylococcus epidermidis Acts on polysaccharide intercellular adhesin(PIA) [88]
Nal-P-113 Denovo AKR-Nal-Nal-GYKRKF-Nal- Porphyromonas gingivalis Down regulates genes related to transportand binding proteins [99]
Human β-
defensin 3
(hBD-3)
Human GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK Stahyloccocus epidermidis Targets icaA, icaD and icaR genes [98]
DJK-5 Denovo VQWRAIRVRVIR Pseudomonas aeruginosa Suppress spoT promoter activity [96]
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3. Biofilm Resistance to AMPs
3.1. Interaction with EPS
It is thought that biofilm mediated resistance to AMPs is mainly due to their interaction with
EPS, however t e ex ct mechanism of interaction remained unknown in large number of cases [102].
Although mos of the substance in EPS a e negatively charged, the positively charged exopolymer
PIA (which is composed of poly-N-acetyl glucosam n ) can cause electrostatic repulsion of the cationic
AMPs [103]. PIA protects S. epidermidis and S. aureus from the bactericidal actions of cationic AMPs
such as LL-37 and human β-defensin [103]. PIA can also protect bacteria in biofilm from ani nic AMP
such as dermcidin (a human epithelial s creted) [102]. So, the role of PIA in protection f bacterial
biofilms may be due to sequestration of AMPs along with electrostatic repulsion [102].
Gram negative bacteria such as P. aeruginosa secrete an ani ic ex racellular polysaccharide known
as algin te which is made up of the uronic cid D-m nnu onate and C-5 epimer-L guluronate [104,105].
Alginate c n teract with positively charge AMPs and protect P. aeruginosa biofilm mbedded cells
from attack of AMPs [106]. Wild-type stra ns such as PAO1, A14 (a mucoid cystic fibr is stra n),
and FRD1 (a mutant which lacks alginate producing ability) can be e ily killed by human leukocytes
and their peptides within 4 h of exposure, [107] but bec me resistant in the prese ce of alginate [107].
Alginate can bind and induce an α-helical conformati n for AMPs such as magainin II and cecropin P1
which is similar to their interaction with cytoplasmic membranes, suggesting that alginate can mediate
hydrophobic i teracti ns with AMPs despite its hydrophilic nature [106]. Alginate can trap AMPs in
hydrophobic microdomains which consist of yranosyl C–H groups t at are in ucibl upon fo mation
of AMPs-alginate complexes due to charge neutralization between the two spec es [108]. H wever,
with the exception of cystic fibrosis, mucoid strains of P. aeruginosa account for only 1% of isolates from
infections [109] so the role of mucoid strains in medical device related infecti ns i l mited. In contrast
to mucoid str ins, non-mu id strains contain low lev ls of alg ate [110] but can us either Pel or Psl
(a structural cationic xopolysaccharide) to develop biofilms [111].
3.2. Adaptive Resistance Mechanism
Staphylococci have a peptide sensing system known as aps, which was first recognized in S.
epidermidis [112]. The aps consist of two-component system that has a sensor histidine kinase (ApsS)
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and a DNA-binding response regulator (ApsR). A third component (ApsX) is also found only in some
staphylococci species [112]. This aps system can protect Gram positive bacteria including methicillin
resistant S. aureus (MRSA) strains from action of AMPs [113]. The aps system upregulates D-alanylation
of teichoic acid and increases the expression of putative AMP efflux pumps [114]. A D-alanine deficient
mutant of E. faecalis produced less biofilm but was more resistant to AMPs than the wild type [115].
The PhoP/PhoQ genetic system found in P. aeruginosa and Salmonella enterica [116] is used to sense
AMPs [117]. This system tends to change the structure of LPS by addition of aminoarabinose to lipid
A, which has the effect of decreasing the net negative charge of lipopolysaccharides [118]. Therefore,
this system may also confer resistance of biofilm bacteria to AMPs. A two-component regulatory
system pmrA-pmrB identified in P. aeruginosa that regulates resistance to polymyxin B, polymyxins E,
cattle indolicidin and LL-37 [119] modifies lipopolysaccharides in the outer membrane of bacteria and
this reduces the AMPs interaction with the outer membrane [120,121] this confering resistance.
3.3. Heterogeneity
Biofilms consist of structurally and functionally diverse bacterial populations and maintain a
micro-environment which controls microbial activity, intracellular signaling and metabolic and genetic
material exchange [122]. These properties can establish cellular and communal behaviors which result
in tolerance and persistence of cells in the presence of antimicrobials [122]. For example, colistin can
kill low metabolically active P. aeruginosa in biofilms but cannot destroy metabolically active cells [123].
This resistance to colistin in biofilms may be due to physiological tolerance [124]. E. coli possessing
IncF plasmids can differentiate into structured and unstructured biofilms and can produce genetically
regulated tolerant subpopulations [124]. Colistin can kill a small number of genetically tolerant bacteria
in structured biofilms but can kill a high number of bacteria in unstructured biofilms. [124].
3.4. Synergy of Anti-Biofilm AMPs with Antibiotics
The anti-biofilm activity of AMPs can be enhanced against biofilms by combining them
with antibiotics [125–128]. Combination strategies are useful since they can target a variety of
microbial communities present with different metabolisms cells in low pH, hypoxic or low nutritious
environments [129]. AMP-1018 can prevent initial bacterial attachment to surfaces by inhibiting the
synthesis of (p)ppGpp [23]. When 1018 was used in combination with ceftazidime, ciprofloxacin,
imipenem, or tobramycin, at sub-MIC this combination could inhibit 50% biofilms produced by
P. aeruginosa, E. coli, A. baumannii, K. pneumoniae, S. enterica, and methicillin-resistant S. aureus
(MRSA) [23]. Similarly, colistin in combination with temporin A (TEMP-A), citropin 1.1 (CIT-1.1) and
tachyplesin I (TP-I-L) can eradiate mature biofilms of drug resistant P. aeruginosa and S. aureus [130].
AMPs can act synergistically with antibiotics against biofilm following two types of mechanism. Firstly,
AMPs-antibiotic combinations can degrade biofilms matrix then AMPs act alone and disperse biofilms
embedded cells [131]. AMP-antibiotic combinations can also be used against fungal biofilms [132].
An antifungal plant defensin derived peptide HsLin06_18 acts synergistically with caspofungin against
Candida glabrata and Candida albicans. HsLin06_18 was shown to act by permeabilization cell membrane
which facilitated caspofungin penetration into the fungal cells, inducing death at a sub-inhibitory
concentration [132].
4. Future Considerations
Treating bacterial infections caused by biofilm-producing microorganisms is a troublesome task
and a major challenge for health care systems. Antibiotic therapy or antibiotic releasing products are not
adequate to control biofilm related infections, particularly due to the emergence of antibiotic resistant
infections. Currently, there is no clear answer for the management and prevention of these infections.
Use of very high concentrations of antibiotics in attempts to disrupt or prevent biofilm formation
can be associated with cytotoxicity and poor prognosis. Hence, finding an alternative class of drugs
to address biofilm-related infections represents a promising strategy. AMPs have broad-spectrum
Materials 2018, 11, 2468 9 of 15
antimicrobial activity and are generally immune to development of bacterial resistance [45,133] and
can work synergistically with first line antibiotics. AMPs have several promising characteristics that
can be used to inhibit biofilms. However, there is limited information on the interaction of AMPs with
biofilm components. More research is needed to understand their precise mechanisms of action such
as inhibiting QS signals that restrict biofilm formation and interfere with signaling pathways involved
in the synthesis of EPS. Molecular modelling approaches may provide insights on action of AMPs on
biofilms. AMP-AMP and AMP-drug combinations that can induce biofilm matrix degradation could
be the potential areas of future anti-biofilm research.
In conclusion, this review found that AMPs have a variety of active anti-biofilm mechanisms
that could be exploited for clinical applications to eradicate biofilms. It is clear that AMPs have
high potential for further development as an active anti-biofilm agent, particularly in the high-risk
environments such as hospital settings. AMPs could be used as a stand-alone therapy or in combination
with other antimicrobials to eradicate biofilms. Further in vivo investigations are warranted to better
understand the complex host environment that may affect their efficacy by reducing their activity and
stability. Moreover, the role of immunomodulatory activities must be evaluated in complex biofilm
environment in vivo.
Funding: This research was funded by Australian Research Council (ARC) discovery project funding scheme
(project number DP160101664).
Acknowledgments: The first author received PhD scholarship from Higher Education Commission (HEC) of
Pakistan and the University of New South Wales, Australia.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Costerton, J.W.; Stewart, P.S.; Greenberg, E.P. Bacterial biofilms: A common cause of persistent infections.
Science 1999, 284, 1318–1322. [CrossRef] [PubMed]
2. Hall-Stoodley, L.; Stoodley, P. Evolving concepts in biofilm infections. Cell. Microbiol. 2009, 11, 1034–1043.
[CrossRef] [PubMed]
3. Hall-Stoodley, L.; Stoodley, P.; Kathju, S.; Høiby, N.; Moser, C.; William Costerton, J.; Moter, A.; Bjarnsholt, T.
Towards diagnostic guidelines for biofilm-associated infections. FEMS Immun. Med. Microbiol. 2012, 65,
127–145. [CrossRef] [PubMed]
4. Roy, R.; Tiwari, M.; Donelli, G.; Tiwari, V. Strategies for combating bacterial biofilms: A focus on anti-biofilm
agents and their mechanisms of action. Virulence 2018, 9, 522–554. [CrossRef] [PubMed]
5. Costerton, J.W.; Cheng, K.J.; Geesey, G.G.; Ladd, T.I.; Nickel, J.C.; Dasgupta, M.; Marrie, T.J. Bacterial biofilms
in nature and disease. Annu. Rev. Microbiol. 1987, 41, 435–464. [CrossRef] [PubMed]
6. Anwar, H.; Dasgupta, M.K.; Costerton, J.W. Testing the susceptibility of bacteria in biofilms to antibacterial
agents. Antimicrob. Agents Chemother. 1990, 34, 2043–2046. [CrossRef] [PubMed]
7. Matz, C.; Bergfeld, T.; Rice, S.A.; Kjelleberg, S. Microcolonies, quorum sensing and cytotoxicity determine
the survival of Pseudomonas aeruginosa biofilms exposed to protozoan grazing. Environ. Microbiol. 2004, 6,
218–226. [CrossRef] [PubMed]
8. Shirtliff, M.E.; Peters, B.M.; Jabra-Rizk, M.A. Cross-kingdom interactions: Candida albicans and bacteria.
FEMS Microbiol. Lett 2009, 299, 1–8. [CrossRef] [PubMed]
9. Flemming, H.C.; Wingender, J. The biofilm matrix. Nat. Rev. Microbiol. 2010, 8, 623–633. [CrossRef] [PubMed]
10. Stoodley, P.; Sauer, K.; Davies, D.G.; Costerton, J.W. Biofilms as complex differentiated communities. Ann.
Rev. Microbiol. 2002, 56, 187–209. [CrossRef]
11. De la Fuente-Núñez, C.; Reffuveille, F.; Fernández, L.; Hancock, R.E. Bacterial biofilm development as a
multicellular adaptation: Antibiotic resistance and new therapeutic strategies. Curr. Opin. Microbiol. 2013,
16, 580–589. [CrossRef] [PubMed]
12. Hall-Stoodley, L.; Costerton, J.W.; Stoodley, P. Bacterial biofilms: From the natural environment to infectious
diseases. Nat. Rev. Microbiol. 2004, 2, 95. [CrossRef] [PubMed]
Materials 2018, 11, 2468 10 of 15
13. Porat, Y.; Marynka, K.; Tam, A.; Steinberg, D.; Mor, A. Acyl-substituted dermaseptin S4 derivatives with
improved bactericidal properties, including on oral microflora. Antimicrob. Agents Chemother. 2006, 50,
4153–4160. [CrossRef] [PubMed]
14. De la Fuente-Nunez, C.; Reffuveille, F.; Mansour, S.C.; Reckseidler-Zenteno, S.L.; Hernandez, D.;
Brackman, G.; Coenye, T.; Hancock, R.E. D-enantiomeric peptides that eradicate wild-type and multidrug-
resistant biofilms and protect against lethal Pseudomonas aeruginosa infections. Chem. Biol. 2015, 22, 196–205.
[CrossRef] [PubMed]
15. De la Fuente-Núñez, C.; Reffuveille, F.; Haney, E.F.; Straus, S.K.; Hancock, R.E. Broad-spectrum anti-biofilm
peptide that targets a cellular stress response. PloS. Pathog. 2014, 10, e1004152. [CrossRef] [PubMed]
16. Donlan, R.M. Biofilms: Microbial Life on Surfaces. Emerg. Inf. Dis. 2002, 8, 881–890. [CrossRef] [PubMed]
17. Stoica, P.; Chifiriuc, M.C.; Rapa, M.; Lazăr, V. Overview of biofilm-related problems in medical devices.
In Biofilms and Implantable Medical Devices; Deng, Y., Lv, W., Eds.; Woodhead Publishing: Cambridge, UK,
2017; pp. 3–23.
18. Dalton, H.M.; March, P.E. Molecular genetics of bacterial attachment and biofouling. Curr. Opin. Biotechnol.
1998, 9, 252–255. [CrossRef]
19. Garrett, T.R.; Bhakoo, M.; Zhang, Z. Bacterial adhesion and biofilms on surfaces. Prog. Nat. Sci. 2008, 18,
1049–1056. [CrossRef]
20. Whittaker, C.J.; Klier, C.M.; Kolenbrander, P.E. Mechanisms of adhesion by oral bacteria. Ann. Rev. Microbiol.
1996, 50, 513–552. [CrossRef] [PubMed]
21. Costerton, J.W. Introduction to biofilm. Int. J. Antimicrob. Agents. 1999, 11, 217–221. [CrossRef]
22. de la Fuente-Núñez, C.; Cardoso, M.H.; de Souza Cândido, E.; Franco, O.L.; Hancock, R.E. Synthetic
antibiofilm peptides. Biochimic. Biophys. Acta. Biomem. 2016, 1858, 1061–1069. [CrossRef] [PubMed]
23. Reffuveille, F.; de la Fuente-Núñez, C.; Mansour, S.; Hancock, R.E.W. A Broad-Spectrum Antibiofilm Peptide
Enhances Antibiotic Action against Bacterial Biofilms. Antmicrob. Agents Chemother. 2014, 58, 5363–5371.
[CrossRef] [PubMed]
24. Stewart, P.S. Theoretical aspects of antibiotic diffusion into microbial biofilms. Antmicrob. Agents Chemother.
1996, 40, 2517–2522. [CrossRef]
25. Mah, T.-F.C.; O’toole, G.A. Mechanisms of biofilm resistance to antimicrobial agents. Trends. Microbiol. 2001,
9, 34–39. [CrossRef]
26. Arciola, C.R.; Campoccia, D.; Speziale, P.; Montanaro, L.; Costerton, J.W. Biofilm formation in Staphylococcus
implant infections. A review of molecular mechanisms and implications for biofilm-resistant materials.
Biomaterials 2012, 33, 5967–5982. [CrossRef] [PubMed]
27. Lewis, K. Riddle of biofilm resistance. Antmicrob. Agents Chemother. 2001, 45, 999–1007. [CrossRef] [PubMed]
28. Hoiby, N.; Ciofu, O.; Johansen, H.K.; Song, Z.J.; Moser, C.; Jensen, P.O.; Molin, S.; Givskov, M.;
Tolker-Nielsen, T.; Bjarnsholt, T. The clinical impact of bacterial biofilms. Int. J. Oral Sci. 2011, 3, 55–65.
[CrossRef] [PubMed]
29. Stewart, P.S.; Roe, F.; Rayner, J.; Elkins, J.G.; Lewandowski, Z.; Ochsner, U.A.; Hassett, D.J. Effect of catalase
on hydrogen peroxide penetration into Pseudomonas aeruginosa biofilms. Appl. Environ. Microbiol. 2000, 66,
836–838. [CrossRef] [PubMed]
30. Fux, C.; Costerton, J.W.; Stewart, P.S.; Stoodley, P. Survival strategies of infectious biofilms. Trends Microbiol.
2005, 13, 34–40. [CrossRef] [PubMed]
31. Hoiby, N.; Bjarnsholt, T.; Givskov, M.; Molin, S.; Ciofu, O. Antibiotic resistance of bacterial biofilms. Int. J.
Antimicrob. Agents 2010, 35, 322–332. [CrossRef]
32. Mah, T.F. Biofilm-specific antibiotic resistance. Future Microbiol. 2012, 7, 1061–1072. [CrossRef] [PubMed]
33. Donlan, R.M. Biofilm formation: A clinically relevant microbiological process. Clin. Infec. Dis. 2001, 33,
1387–1392. [CrossRef] [PubMed]
34. Høiby, N.; Bjarnsholt, T.; Moser, C.; Bassi, G.; Coenye, T.; Donelli, G.; Hall-Stoodley, L.; Hola, V.;
Imbert, C.; Kirketerp-Møller, K. ESCMID∗ guideline for the diagnosis and treatment of biofilm infections.
Clin. Microbiol. Infect. 2015, 21, S1–S25. [CrossRef] [PubMed]
35. Romling, U.; Kjelleberg, S.; Normark, S.; Nyman, L.; Uhlin, B.E.; Akerlund, B. Microbial biofilm formation:
A need to act. J. Intern. Med. 2014, 276, 98–110. [CrossRef] [PubMed]
36. Romling, U.; Balsalobre, C. Biofilm infections, their resilience to therapy and innovative treatment strategies.
J. Intern. Med. 2012, 272, 541–561. [CrossRef] [PubMed]
Materials 2018, 11, 2468 11 of 15
37. Bryers, J.D. Medical Biofilms. Biotechnol. Bioeng. 2008, 100, 1–18. [CrossRef] [PubMed]
38. Costerton, J.W.; Montanaro, L.; Arciola, C.R. Biofilm in implant infections: Its production and regulation.
Int. J. Art. Organs 2005, 28, 1062–1068. [CrossRef]
39. Costerton, W.; Veeh, R.; Shirtliff, M.; Pasmore, M.; Post, C.; Ehrlich, G. The application of biofilm science
to the study and control of chronic bacterial infections. J. Clin. Investig. 2003, 112, 1466–1477. [CrossRef]
[PubMed]
40. Veerachamy, S.; Yarlagadda, T.; Manivasagam, G.; Yarlagadda, P.K. Bacterial adherence and biofilm formation
on medical implants: A review. Proc. Inst. Mech. Eng. Part. H J. Eng. Med. 2014, 228, 1083–1099. [CrossRef]
[PubMed]
41. Bryers, J.D.; Ratner, B.D. Bioinspired implant materials befuddle bacteria. ASM News-Am. Soc. Microbiol.
2004, 70, 232.
42. Castelli, P.; Caronno, R.; Ferrarese, S.; Mantovani, V.; Piffaretti, G.; Tozzi, M.; Lomazzi, C.; Rivolta, N.; Sala, A.
New trends in prosthesis infection in cardiovascular surgery. Surg. Infect. 2006, 7 (Suppl. 2), S45–S47.
[CrossRef]
43. Carmen, J.C.; Roeder, B.L.; Nelson, J.L.; Ogilvie, R.L.R.; Robison, R.A.; Schaalje, G.B.; Pitt, W.G. Treatment of
biofilm infections on implants with low-frequency ultrasound and antibiotics. Am. J. Infect. Cont. 2005, 33,
78–82. [CrossRef] [PubMed]
44. Paterson, I.K.; Hoyle, A.; Ochoa, G.; Baker-Austin, C.; Taylor, N.G. Optimising antibiotic usage to treat
bacterial infections. Sci Rep 2016, 6, 37853. [CrossRef] [PubMed]
45. Bahar, A.A.; Ren, D. Antimicrobial peptides. Pharmaceuticals 2013, 6, 1543–1575. [CrossRef] [PubMed]
46. Brown, K.L.; Hancock, R.E. Cationic host defense (antimicrobial) peptides. Curr. Opin. Immunol. 2006, 18,
24–30. [CrossRef] [PubMed]
47. Groenink, J.; Walgreen-Weterings, E.; van‘t Hof, W.; Veerman, E.I.; Nieuw Amerongen, A.V. Cationic
amphipathic peptides, derived from bovine and human lactoferrins, with antimicrobial activity against oral
pathogens. FEMS Microbiol. Lett. 1999, 179, 217–222. [CrossRef] [PubMed]
48. Bradshaw, J.P. Cationic antimicrobial peptides. BioDrugs 2003, 17, 233–240. [CrossRef] [PubMed]
49. Huang, Y.; Huang, J.; Chen, Y. Alpha-helical cationic antimicrobial peptides: Relationships of structure and
function. Protein Cell 2010, 1, 143–152. [CrossRef]
50. Harris, F.; Dennison, S.R.; Phoenix, D.A. Anionic antimicrobial peptides from eukaryotic organisms.
Curr. Prot. Pep. Sci. 2009, 10, 585–606. [CrossRef]
51. Batoni, G.; Maisetta, G.; Esin, S. Antimicrobial peptides and their interaction with biofilms of medically
relevant bacteria. Biochim. Biophys. Acta 2016, 1858, 1044–1060. [CrossRef]
52. Segev-Zarko, L.; Saar-Dover, R.; Brumfeld, V.; Mangoni, M.L.; Shai, Y. Mechanisms of biofilm inhibition and
degradation by antimicrobial peptides. Biochem. J. 2015, 468, 259–270. [CrossRef] [PubMed]
53. Bowdish, D.M.; Davidson, D.J.; Hancock, R.E. A re-evaluation of the role of host defence peptides in
mammalian immunity. Curr. Protein Pept. Sci. 2005, 6, 35–51. [CrossRef] [PubMed]
54. Boman, H.G. Peptide antibiotics and their role in innate immunity. Ann. Rev. Immunol. 1995, 13, 61–92.
[CrossRef] [PubMed]
55. Tossi, A.; Sandri, L.; Giangaspero, A. Amphipathic, alpha-helical antimicrobial peptides. Biopolymers 2000,
55, 4–30. [CrossRef]
56. Ebenhan, T.; Gheysens, O.; Kruger, H.G.; Zeevaart, J.R.; Sathekge, M.M. Antimicrobial peptides: Their role as
infection-selective tracers for molecular imaging. BioMed. Res. Int. 2014, 2014, 867381. [CrossRef] [PubMed]
57. Tossi, A.; Sandri, L. Molecular diversity in gene-encoded, cationic antimicrobial polypeptides. Curr. Pharm. Des.
2002, 8, 743–761. [CrossRef] [PubMed]
58. Ganz, T. Defensins: Antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 2003, 3, 710–720. [CrossRef]
59. Lehrer, R.I. Primate defensins. Nat. Rev. Microbiol. 2004, 2, 727–738. [CrossRef]
60. Takahashi, D.; Shukla, S.K.; Prakash, O.; Zhang, G. Structural determinants of host defense peptides for
antimicrobial activity and target cell selectivity. Biochimie 2010, 92, 1236–1241. [CrossRef]
61. Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature 2002, 415, 389. [CrossRef]
62. Selsted, M.E.; Harwig, S.S. Determination of the disulfide array in the human defensin HNP-2. A covalently
cyclized peptide. J. Biol. Chem. 1989, 264, 4003–4007. [PubMed]
63. Tang, Y.Q.; Selsted, M.E. Characterization of the disulfide motif in BNBD-12, an antimicrobial beta-defensin
peptide from bovine neutrophils. J. Biol. Chem. 1993, 268, 6649–6653. [PubMed]
Materials 2018, 11, 2468 12 of 15
64. Cruz, J.; Ortiz, C.; Guzman, F.; Fernandez-Lafuente, R.; Torres, R. Antimicrobial peptides: Promising
compounds against pathogenic microorganisms. Curr. Med. Chem. 2014, 21, 2299–2321. [CrossRef] [PubMed]
65. Su, L.Y.; Willner, D.L.; Segall, A.M. An antimicrobial peptide that targets DNA repair intermediates in vitro
inhibits Salmonella growth within murine macrophages. Antimicrob. Agents Chemother. 2010, 54, 1888–1899.
[CrossRef] [PubMed]
66. Brogden, K.A. Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol.
2005, 3, 238–250. [CrossRef] [PubMed]
67. Kragol, G.; Lovas, S.; Varadi, G.; Condie, B.A.; Hoffmann, R.; Otvos, L. The antibacterial peptide pyrrhocoricin
inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding. Biochemistry 2001, 40,
3016–3026. [CrossRef] [PubMed]
68. Conti, S.; Radicioni, G.; Ciociola, T.; Longhi, R.; Polonelli, L.; Gatti, R.; Cabras, T.; Messana, I.; Castagnola, M.;
Vitali, A. Structural and functional studies on a proline-rich peptide isolated from swine saliva endowed
with antifungal activity towards Cryptococcus neoformans. Biochim. Biophys. Acta Biomem. 2013, 1828,
1066–1074. [CrossRef]
69. Shai, Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by
alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochimic. Biophys. Acta 1999,
1462, 55–70. [CrossRef]
70. Peschel, A.; Sahl, H.-G. The co-evolution of host cationic antimicrobial peptides and microbial resistance.
Nat. Rev. Microbiol. 2006, 4, 529. [CrossRef]
71. Schuller, F.; Benz, R.; Sahl, H.G. The peptide antibiotic subtilin acts by formation of voltage-dependent
multi-state pores in bacterial and artificial membranes. Eur. J. Biochem. 1989, 182, 181–186. [CrossRef]
72. Tennessen, J.A. Molecular evolution of animal antimicrobial peptides: Widespread moderate positive
selection. J. Evol. Biol. 2005, 18, 1387–1394. [CrossRef] [PubMed]
73. Wimley, W.C.; Hristova, K. Antimicrobial Peptides: Successes, challenges and unanswered questions.
J. Memb. Biol. 2011, 239, 27–34. [CrossRef] [PubMed]
74. Straus, S.K.; Hancock, R.E. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin:
Comparison with cationic antimicrobial peptides and lipopeptides. Biochim. Biophys. Acta 2006, 1758,
1215–1223. [CrossRef]
75. Sang, Y.; Blecha, F. Antimicrobial peptides and bacteriocins: Alternatives to traditional antibiotics.
Anim. Health Res. Rev. 2008, 9, 227–235. [CrossRef] [PubMed]
76. Haney, E.F.; Mansour, S.C.; Hancock, R.E. Antimicrobial Peptides: An Introduction. Meth. Mol. Biol. 2017,
1548, 3–22. [CrossRef]
77. Sun, E.; Belanger, C.R.; Haney, E.F.; Hancock, R.E. Host defense (antimicrobial) peptides. In Peptide
Applications in Biomedicine, Biotechnology and Bioengineering; Elsevier: Amsterdam, the Netherlands, 2018;
pp. 253–285.
78. Okuda, K.; Zendo, T.; Sugimoto, S.; Iwase, T.; Tajima, A.; Yamada, S.; Sonomoto, K.; Mizunoe, Y. Effects of
bacteriocins on methicillin-resistant Staphylococcus aureus biofilm. Antimicrob. Agents Chemother. 2013, 57,
5572–5579. [CrossRef]
79. Pulido, D.; Prats-Ejarque, G.; Villalba, C.; Albacar, M.; González-López, J.J.; Torrent, M.; Moussaoui, M.;
Boix, E. A novel RNase 3/ECP peptide for Pseudomonas aeruginosa biofilm eradication. Combining
antimicrobial, lipopolysaccharide binding and cell agglutinating activities. Antimicrob. Agents Chemother.
2016, 60, 6313–6325. [CrossRef]
80. Venge, P. Eosinophil cationic protein (ECP): Molecular and biological properties and the use of ECP as a
marker of eosinophil activation in disease. Clin. Exp. Allergy 1999, 29, 1172–1186. [CrossRef]
81. Acharya, K.R.; Ackerman, S.J. Eosinophil granule proteins: Form and function. J. Biol. Chem. 2014. [CrossRef]
82. Luca, V.; Stringaro, A.; Colone, M.; Pini, A.; Mangoni, M.L. Esculentin(1-21), an amphibian skin
membrane-active peptide with potent activity on both planktonic and biofilm cells of the bacterial pathogen
Pseudomonas aeruginosa. Cell. Mol. Life. Sci. 2013, 70, 2773–2786. [CrossRef]
83. Nagant, C.; Pitts, B.; Stewart, P.S.; Feng, Y.; Savage, P.B.; Dehaye, J.P. Study of the effect of antimicrobial
peptide mimic, CSA-13, on an established biofilm formed by P seudomonas aeruginosa. Microbiologyopen
2013, 2, 318–325. [CrossRef] [PubMed]
84. Overhage, J.; Campisano, A.; Bains, M.; Torfs, E.C.; Rehm, B.H.; Hancock, R.E. Human host defense peptide
LL-37 prevents bacterial biofilm formation. Infect. Immun. 2008, 76, 4176–4182. [CrossRef] [PubMed]
Materials 2018, 11, 2468 13 of 15
85. de la Fuente-Núñez, C.; Korolik, V.; Bains, M.; Nguyen, U.; Breidenstein, E.B.M.; Horsman, S.; Lewenza, S.;
Burrows, L.; Hancock, R.E.W. Inhibition of Bacterial Biofilm Formation and Swarming Motility by a Small
Synthetic Cationic Peptide. Antimicrob. Agents Chemother. 2012, 56, 2696–2704. [CrossRef] [PubMed]
86. Jorge, P.; Lourenco, A.; Pereira, M.O. New trends in peptide-based anti-biofilm strategies: A review of recent
achievements and bioinformatic approaches. Biofouling 2012, 28, 1033–1061. [CrossRef] [PubMed]
87. Ansari, J.M.; Abraham, N.M.; Massaro, J.; Murphy, K.; Smith-Carpenter, J.; Fikrig, E. Anti-biofilm activity of
a self-aggregating peptide against Streptococcus mutans. Front. Microbiol. 2017, 8, 488. [CrossRef] [PubMed]
88. Gordya, N.; Yakovlev, A.; Kruglikova, A.; Tulin, D.; Potolitsina, E.; Suborova, T.; Bordo, D.; Rosano, C.;
Chernysh, S. Natural antimicrobial peptide complexes in the fighting of antibiotic resistant biofilms:
Calliphora vicina medicinal maggots. PLoS ONE 2017, 12, e0173559. [CrossRef] [PubMed]
89. Brancatisano, F.L.; Maisetta, G.; Di Luca, M.; Esin, S.; Bottai, D.; Bizzarri, R.; Campa, M.; Batoni, G. Inhibitory
effect of the human liver-derived antimicrobial peptide hepcidin 20 on biofilms of polysaccharide intercellular
adhesin (PIA)-positive and PIA-negative strains of Staphylococcus epidermidis. Biofouling 2014, 30, 435–446.
[CrossRef]
90. Quiles, F.; Saadi, S.; Francius, G.; Bacharouche, J.; Humbert, F. In situ and real time investigation of
the evolution of a Pseudomonas fluorescens nascent biofilm in the presence of an antimicrobial peptide.
Biochimic. Biophys. Acta 2016, 1858, 75–84. [CrossRef]
91. Libardo, M.D.J.; Bahar, A.A.; Ma, B.; Fu, R.; McCormick, L.E.; Zhao, J.; McCallum, S.A.; Nussinov, R.; Ren, D.;
Angeles-Boza, A.M.; et al. Nuclease activity gives an edge to host-defense peptide piscidin 3 over piscidin 1,
rendering it more effective against persisters and biofilms. FEBS J. 2017, 284, 3662–3683. [CrossRef]
92. Pletzer, D.; Coleman, S.R.; Hancock, R.E. Anti-biofilm peptides as a new weapon in antimicrobial warfare.
Curr. Opin. Microbiol. 2016, 33, 35–40. [CrossRef]
93. Potrykus, K.; Cashel, M. (p)ppGpp: Still magical? Ann. Rev. Microbiol. 2008, 62, 35–51. [CrossRef] [PubMed]
94. Braeken, K.; Moris, M.; Daniels, R.; Vanderleyden, J.; Michiels, J. New horizons for (p) ppGpp in bacterial
and plant physiology. Trends Microbiol. 2006, 14, 45–54. [CrossRef] [PubMed]
95. Åberg, A.; Shingler, V.; Balsalobre, C. (p) ppGpp regulates type 1 fimbriation of Escherichia coli by modulating
the expression of the site-specific recombinase FimB. Mol. Microbiol. 2006, 60, 1520–1533. [CrossRef]
[PubMed]
96. Pletzer, D.; Wolfmeier, H.; Bains, M.; Hancock, R.E.W. Synthetic Peptides to Target Stringent
Response-Controlled Virulence in a Pseudomonas aeruginosa Murine Cutaneous Infection Model.
Front. Microbiol. 2017, 8. [CrossRef] [PubMed]
97. Rohde, H.; Frankenberger, S.; Zähringer, U.; Mack, D. Structure, function and contribution of polysaccharide
intercellular adhesin (PIA) to Staphylococcus epidermidis biofilm formation and pathogenesis of
biomaterial-associated infections. Eur. J. Cell. Biol. 2010, 89, 103–111. [CrossRef] [PubMed]
98. Zhu, C.; Tan, H.; Cheng, T.; Shen, H.; Shao, J.; Guo, Y.; Shi, S.; Zhang, X. Human beta-defensin 3 inhibits
antibiotic-resistant Staphylococcus biofilm formation. J. Surg. Res. 2013, 183, 204–213. [CrossRef]
99. Wang, H.-Y.; Lin, L.; Tan, L.-S.; Yu, H.-Y.; Cheng, J.-W.; Pan, Y.-P. Molecular pathways underlying inhibitory
effect of antimicrobial peptide Nal-P-113 on bacteria biofilms formation of Porphyromonas gingivalis W83
by DNA microarray. BMC Microbiol. 2017, 17, 37. [CrossRef]
100. Hinsa, S.M.; Espinosa-Urgel, M.; Ramos, J.L.; O’Toole, G.A. Transition from reversible to irreversible
attachment during biofilm formation by Pseudomonas fluorescens WCS365 requires an ABC transporter
and a large secreted protein. Mol. Microbiol. 2003, 49, 905–918. [CrossRef]
101. Andersen, R.N.; Ganeshkumar, N.; Kolenbrander, P.E. Cloning of the Streptococcus gordonii PK488 gene,
encoding an adhesin which mediates coaggregation with Actinomyces naeslundii PK606. Infect. Immun.
1993, 61, 981–987.
102. Otto, M. Bacterial evasion of antimicrobial peptides by biofilm formation. Curr. Top. Microbiol. Immunol.
2006, 306, 251–258.
103. Vuong, C.; Voyich, J.M.; Fischer, E.R.; Braughton, K.R.; Whitney, A.R.; DeLeo, F.R.; Otto, M. Polysaccharide
intercellular adhesin (PIA) protects Staphylococcus epidermidis against major components of the human
innate immune system. Cell. Microbiol. 2004, 6, 269–275. [CrossRef] [PubMed]
104. Gacesa, P. Bacterial alginate biosynthesis-recent progress and future prospects. Microbiology 1998, 144,
1133–1143. [CrossRef] [PubMed]
Materials 2018, 11, 2468 14 of 15
105. Evans, L.R.; Linker, A. Production and characterization of the slime polysaccharide of Pseudomonas
aeruginosa. J. Bacteriol. 1973, 116, 915–924. [PubMed]
106. Chan, C.; Burrows, L.L.; Deber, C.M. Helix induction in antimicrobial peptides by alginate in biofilms.
J. Biol. Chem. 2004, 279, 38749–38754. [CrossRef] [PubMed]
107. Leid, J.G.; Willson, C.J.; Shirtliff, M.E.; Hassett, D.J.; Parsek, M.R.; Jeffers, A.K. The exopolysaccharide
alginate protects Pseudomonas aeruginosa biofilm bacteria from IFN-gamma-mediated macrophage killing.
J. Immunol. 2005, 175, 7512–7518. [CrossRef] [PubMed]
108. Kuo, H.H.; Chan, C.; Burrows, L.L.; Deber, C.M. Hydrophobic interactions in complexes of antimicrobial
peptides with bacterial polysaccharides. Chem. Biol. Drug. Des. 2007, 69, 405–412. [CrossRef]
109. Doggett, R.G.; Harrison, G.M.; Stillwell, R.N.; Wallis, E.S. An atypical Pseudomonas aeruginosa associated
with cystic fibrosis of the pancreas. J. Ped. 1966, 68, 215–221. [CrossRef]
110. Stapper, A.P.; Narasimhan, G.; Ohman, D.E.; Barakat, J.; Hentzer, M.; Molin, S.; Kharazmi, A.; Hoiby, N.;
Mathee, K. Alginate production affects Pseudomonas aeruginosa biofilm development and architecture, but
is not essential for biofilm formation. J. Med. Microbiol. 2004, 53, 679–690. [CrossRef] [PubMed]
111. Colvin, K.M.; Irie, Y.; Tart, C.S.; Urbano, R.; Whitney, J.C.; Ryder, C.; Howell, P.L.; Wozniak, D.J.; Parsek, M.R.
The Pel and Psl polysaccharides provide Pseudomonas aeruginosa structural redundancy within the biofilm
matrix. Environ. Microbiol. 2012, 14, 1913–1928. [CrossRef] [PubMed]
112. Li, M.; Lai, Y.; Villaruz, A.E.; Cha, D.J.; Sturdevant, D.E.; Otto, M. Gram-positive three-component
antimicrobial peptide-sensing system. Proc. Natl. Acad. Sci. USA 2007, 104, 9469–9474. [CrossRef] [PubMed]
113. Yang, S.-J.; Bayer, A.S.; Mishra, N.N.; Meehl, M.; Ledala, N.; Yeaman, M.R.; Xiong, Y.Q.; Cheung, A.L.
The Staphylococcus aureus two-component regulatory system, GraRS, senses and confers resistance to
selected cationic antimicrobial peptides. Infect. Immun. 2012, 80, 74–81. [CrossRef] [PubMed]
114. Otto, M. Bacterial sensing of antimicrobial peptides. Cont. Microbiol. 2009, 16, 136–149. [CrossRef]
115. Fabretti, F.; Theilacker, C.; Baldassarri, L.; Kaczynski, Z.; Kropec, A.; Holst, O.; Huebner, J. Alanine esters
of enterococcal lipoteichoic acid play a role in biofilm formation and resistance to antimicrobial peptides.
Infect. Immun. 2006, 74, 4164–4171. [CrossRef] [PubMed]
116. Skiada, A.; Markogiannakis, A.; Plachouras, D.; Daikos, G.L. Adaptive resistance to cationic compounds in
Pseudomonas aeruginosa. Int. J. Antimicrob. Aents 2011, 37, 187–193. [CrossRef] [PubMed]
117. Bader, M.W.; Sanowar, S.; Daley, M.E.; Schneider, A.R.; Cho, U.; Xu, W.; Klevit, R.E.; Le Moual, H.; Miller, S.I.
Recognition of antimicrobial peptides by a bacterial sensor kinase. Cell 2005, 122, 461–472. [CrossRef]
[PubMed]
118. Ramsey, M.M.; Whiteley, M. Pseudomonas aeruginosa attachment and biofilm development in dynamic
environments. Mol. Microbiol. 2004, 53, 1075–1087. [CrossRef]
119. McPhee, J.B.; Lewenza, S.; Hancock, R.E. Cationic antimicrobial peptides activate a two-component
regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides
in Pseudomonas aeruginosa. Mol. Microbiol. 2003, 50, 205–217. [CrossRef] [PubMed]
120. Gunn, J.S.; Lim, K.B.; Krueger, J.; Kim, K.; Guo, L.; Hackett, M.; Miller, S.I. PmrA-PmrB-regulated genes
necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. Mol. Microbiol. 1998, 27,
1171–1182. [CrossRef] [PubMed]
121. Gunn, J.S.; Miller, S.I. PhoP-PhoQ activates transcription of pmrAB, encoding a two-component regulatory
system involved in Salmonella typhimurium antimicrobial peptide resistance. J. Bacteriol. 1996, 178,
6857–6864. [CrossRef]
122. Koo, H.; Allan, R.N.; Howlin, R.P.; Hall-Stoodley, L.; Stoodley, P. Targeting microbial biofilms: Current and
prospective therapeutic strategies. Nat. Rev. Microbiol. 2017, 15, 740–755. [CrossRef]
123. Pamp, S.J.; Gjermansen, M.; Johansen, H.K.; Tolker-Nielsen, T. Tolerance to the antimicrobial peptide colistin
in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and
mexAB-oprM genes. Mol. Microbiol. 2008, 68, 223–240. [CrossRef] [PubMed]
124. Folkesson, A.; Haagensen, J.A.; Zampaloni, C.; Sternberg, C.; Molin, S. Biofilm induced tolerance towards
antimicrobial peptides. PLoS ONE 2008, 3, e1891. [CrossRef] [PubMed]
125. Mishra, N.M.; Briers, Y.; Lamberigts, C.; Steenackers, H.; Robijns, S.; Landuyt, B.; Vanderleyden, J.;
Schoofs, L.; Lavigne, R.; Luyten, W. Evaluation of the antibacterial and antibiofilm activities of novel
CRAMP–vancomycin conjugates with diverse linkers. Org. Biomol. Chem. 2015, 13, 7477–7486. [CrossRef]
[PubMed]
Materials 2018, 11, 2468 15 of 15
126. Rudilla, H.; Fusté, E.; Cajal, Y.; Rabanal, F.; Vinuesa, T.; Viñas, M. Synergistic antipseudomonal effects of
synthetic peptide AMP38 and carbapenems. Molecules 2016, 21, 1223. [CrossRef] [PubMed]
127. Ribeiro, S.M.; de la Fuente-Núñez, C.; Baquir, B.; Faria-Junior, C.; Franco, O.L.; Hancock, R.E. Antibiofilm
peptides increase the susceptibility of carbapenemase-producing Klebsiella pneumoniae clinical isolates to
β-lactam antibiotics. Antimicrob. Agents Chemother. 2015, 59, 3906–3912. [CrossRef]
128. Gopal, R.; Kim, Y.G.; Lee, J.H.; Lee, S.K.; Chae, J.D.; Son, B.K.; Seo, C.H.; Park, Y. Synergistic effects and
antibiofilm properties of chimeric peptides against multidrug-resistant Acinetobacter baumannii strains.
Antimicrob. Agents Chemother. 2014, 58, 1622–1629. [CrossRef] [PubMed]
129. Grassi, L.; Maisetta, G.; Esin, S.; Batoni, G. Combination Strategies to Enhance the Efficacy of Antimicrobial
Peptides against Bacterial Biofilms. Front. Microbiol. 2017, 8, 2409. [CrossRef] [PubMed]
130. Jorge, P.; Grzywacz, D.; Kamysz, W.; Lourenço, A.; Pereira, M.O. Searching for new strategies against
biofilm infections: Colistin-AMP combinations against Pseudomonas aeruginosa and Staphylococcus aureus
single-and double-species biofilms. PLoS ONE 2017, 12, e0174654. [CrossRef] [PubMed]
131. Chung, P.Y.; Khanum, R. Antimicrobial peptides as potential anti-biofilm agents against multidrug-resistant
bacteria. J. Microbiol. Immunol. Infect. 2017, 50, 405–410. [CrossRef] [PubMed]
132. Cools, T.L.; Struyfs, C.; Drijfhout, J.W.; Kucharikova, S.; Lobo Romero, C.; Van Dijck, P.; Ramada, M.H.S.;
Bloch, C., Jr.; Cammue, B.P.A.; Thevissen, K. A Linear 19-Mer Plant Defensin-Derived Peptide Acts
Synergistically with Caspofungin against Candida albicans Biofilms. Front. Microbiol. 2017, 8, 2051. [CrossRef]
[PubMed]
133. Mahlapuu, M.; Håkansson, J.; Ringstad, L.; Björn, C. Antimicrobial Peptides: An Emerging Category of
Therapeutic Agents. Front. Cell. Infect. Microbiol. 2016, 6, 194. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
